Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for ...
On July 31, 2024, Adial announced that, after an extensive review of data and information from the Onward Study, it had filed a new patent application to protect core assets and extend IP exclusivity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback